O
TBPH icon

OrbiMed’s Theravance Biopharma TBPH Stock Holding History

OrbiMed’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,370,250
Closed -$12.4K – 145
2022
Q2 		$12.4K Sell
1,370,250
-1,884,463
-58% -$17.4M 0.22% 82
2022
Q1 		$31.1M Sell
3,254,713
-2,719,822
-46% -$26.7M 0.5% 52
2021
Q4 		$66M Buy
5,974,535
+79,376
+1% +$692K 0.85% 41
2021
Q3 		$43.6M Buy
5,895,159
+1,331,114
+29% +$14.9M 0.48% 58
2021
Q2 		$66.3M Sell
4,564,045
-1,655,065
-27% -$31.1M 0.67% 47
2021
Q1 		$127M Hold
6,219,110
– – 1.19% 23
2020
Q4 		$111M Hold
6,219,110
– – 0.97% 29
2020
Q3 		$92M Buy
6,219,110
+3,664,640
+143% +$68.6M 1.16% 25
2020
Q2 		$53.6M Buy
2,554,470
+2,342,925
+1,108% +$60.2M 0.75% 43
2020
Q1 		$4.89M Buy
+211,545
New +$5.29M 0.08% 107

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's TBPH Position: Q3 2022 in Review

OrbiMed sold out of Theravance Biopharma (TBPH) in Q3 2022, closing a stake of 1,370,250 shares — an estimated $12.4K sold.

OrbiMed first reported a position in TBPH in Q1 2020 and held it in 10 quarters. The position peaked at $127M in Q1 2021. 123 funds tracked by Wall St. Rank hold TBPH as of Q3 2022.

  • OrbiMed reported no remaining Theravance Biopharma position as of Q3 2022 after selling out during the quarter.
  • OrbiMed sold 1,370,250 Theravance Biopharma shares in Q3 2022, an estimated $12.4K.
  • OrbiMed first reported a position in Theravance Biopharma in Q1 2020 and held it in 10 quarters.
  • OrbiMed's Theravance Biopharma position peaked at $127M in Q1 2021.
  • 123 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2022.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.